Proposing a new anti-Covid-19 agent by using molecular docking and dynamics simulations
DOI:
https://doi.org/10.1590/Keywords:
SARS-CoV-2, Covid-19, Mpro, Oxoquinoline derivatives, Molecular docking, Molecular dynamicsAbstract
The Covid-19 pandemic, caused by SARS-CoV-2, was responsible for millions of deaths worldwide. The main protease (Mpro) of SARS-CoV-2 is considered one of the important drug targets for the treatment of Covid-19. Recent studies have shown that anisotine should be a potent Mpro inhibitor. In the present work, four oxoquinoline derivatives are proposed as candidates for Mpro inhibitors. The main functional group of these derivatives shows similarity to anisotine, and they are active against the HSV-1, as well as the latter. Molecular docking studies evaluated whether these compounds could be active against Mpro of SARS-CoV-2. Structural modifications were proposed on the oxoquinoline derivative which formed a more stable complex with Mpro and this proposal formed an even more stable complex besides exhibiting improvements in the toxicological profile. Molecular dynamics simulations indicated that derivatives proposed promote greater stabilization by complexing with Mpro than anisotine.
Downloads
References
Abraham M, Alekseenko A, Berg C, Blau C, Briand E, Doijade M, et al. GROMACS 2023.1.2023.
Ahamad S, Kanipakam H, Birla S, Ali MS, Gupta D. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 Mpro, using molecular docking and dynamics simulation studies. Eur J Pharmacol. 2021;890:73664-173676.
Bakowski MA, Beutler N, Wolff KC, Kirkpatrick MG, Chen E, Nguyen TH, et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat Commun. 2021;12:3309-3323.
Bassani D, Pavan M, Bolcato G, Sturlese M, Moro S. Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease Mpro. Pharmaceuticals. 2022;15:180-198.
Berman HM. The protein data bank. Nucleic Acids Res. 2000;28:235-242.
Canzar S, El-Kebir M, Pool R, Elbassioni K, Mark AE, Geerke DP, et al. Charge group partitioning in biomolecular simulation. J Comput Biol. 2013;20:188-198.
Chaudhary M, Tyagi K. A review on molecular docking and it’s application. Int J Adv Res. 2024;12:1141-1153.
Dagur P, Rakshit G, Sheikh M, Biswas A, Jha P, Al-Khafaji K, et al. Target prediction, computational identification, and network-based pharmacology of most potential phytoconstituent in medicinal leaves of Justicia adhatoda against SARS-CoV-2. J Biomol Struct Dyn. 2023;41:3926-3942.
Dannenberg JJ. An introduction to hydrogen bonding. J Am Chem Soc. 1998;120:5604-5604.
Dassault Systèmes BIOVIA, Discovery Studio Visualizer, v20.1, San Diego: Dassault Systèmes, 2019.
Dube PS, Legoabe LJ, Beteck RM. Quinolone: a versatile therapeutic compound class. Mol Divers. 2022;17:1-26.
Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure based drug design strategies. Molecules. 2015;20:13384-13421.
Food & Drug Administration. FDA. Coronavirus (COVID-19) | Drugs: Coronavirus (COVID-19) | Drugs: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs Accessed in may, 2024.
» https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs
Franco LS, Maia RC, Barreiro EJ. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M PRO) through in silico screening supported by molecular docking and a fragment-based pharmacophore model. RSC Med Chem. 2021;12:110-119.
Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective. J Mol Struct. 2021;1229:129489-129497.
Gowrishankar S, Mutyhumanickam S, Kamaladevi A, Karthika C, Jothi R, Boomi P, et al. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study. Food Chem Toxicol. 2021;148:111966-111980.
Ibrahim MAA, Abdelrahman AHM, Hussien TA, Badr EAA, Mohamed TA, El-Seedi HR, et al. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput Biol Med. 2020;126:104046-104056.
Jia Z, Lan X-W, Lu K, Meng X, Jing W-J, Jia S-R, et al. Synthesis, molecular docking, and binding Gibbs free energy calculation of β-nitrostyrene derivatives: Potential inhibitors of SARS-CoV-2 3CL protease. J Mol Struct . 2023;1284:135409.
Jose S, Gupta M, Sharma U, Quintero-Saumeth J, Dwivedi M. Potential of phytocompounds from Brassica oleracea targeting S2-domain of SARS-CoV-2 spike glycoproteins: Structural and molecular insights. J Mol Struct . 2022;1254:132369-132383.
Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, et al. Improvements to the APBS biomolecular solvation software suite. Prot Sci. 2018;27:112-128.
Kar P, Kumar V, Vellingiri B, Sen A, Jaishee N, Anandraj A, et al. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. J Biomol Struct Dyn . 2020;40:1-11.
Kar P, Saleh-E-In MM, Jaishee N, Anandraj A, Kormuth E, Vellingiri B, et al. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19. J Cell Biochem. 2022;123:964-986.
Li, X, Chang J, Chen S, Wang L, Yau TO, Zhao Q, et al. Genomic Feature Analysis of Betacoronavirus Provides Insights into SARS and COVID-19 Pandemics. Front Microbiol. 202;12:614494.
Lipinski CA. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004;1:337-341.
Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, et al. An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. J Chem Theory Comput. 2011;7:4026-4037.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785-2791.
Mslati H, Gentile F, Perez C, Cherkasov A. Comprehensive consensus analysis of SARS-CoV-2 drug repurposing campaigns. J Chem Inf Model. 2021;6:3771-3788.
Neves BJ, Mottin MM, Moreira-Filho JT, Sousa BKP, Mendonça SS, Andrade, CH. Chapter 4-Best Practices for Docking-Based Virtual Screening. Ed. Mohane S. Coumar, Molecular Docking for Computer-Aided Drug Design, Academic Press, 2021, 75-98.
Niranjana SV, Chethan BS, Mahesha, Chethan Prathap KN, Hema MK, Lokanath NK. In-silico investigation of 4-nitro-N-1H-pyrazol-3-ylbenzamide towards its potential use against SARS-CoV-2: a DFT, molecular docking and molecular dynamics study, J Biomol Struct Dyn . 2023;28:1-21.
Padasas BT, Espanõ E, Kim S-H, Song Y, Lee C-K, Kim J-K. COVID-19 Therapeutics: An Update on Effective Treatments Against Infection with SARS-CoV-2 Variants. Immune Netw. 2023;23:e13-37.
Saha P, Bose S, Srivastava AK, Chaudhary AA, Lall R, Prasad S. Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions. Molecules . 2021;26:6783-6807.
Sander T. OSIRIS Property Explorer. SwitzerlandIdorsia Pharmaceuticals Ltd, 2001. https://www.organic-chemistry.org/prog/peo/ Accessed in: march, 2024.
» https://www.organic-chemistry.org/prog/peo/
Schmid N, Eichenberger AP, Choutko A, Riniker S, Winger M, Mark AE, et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur Biophys J. 2011;40:843-856.
SPARTAN’10, Wavefunction Inc. Irvine, CA 92612, U.S.A., 2011.
Swain SS, Panda SK., Luyten W. Phytochemicals against SARS-CoV as potential drug leads. Biomed J. 2021;44:74-85.
Tan J, Verschuere KHG, Anand K, Shen, J, Yang M, Xu Y, et al. pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses. J Mol Biol. 2005;354:25-40.
The PyMOL Molecular Graphics System, Version 2.4 Schrödinger, LLC, 2020, [s.d.].
Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem . 2010;31:455-461.
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J Med Chem. 2002;45:2615-2623.
Verli H, Barreiro E J. Um paradigma da química medicinal: a flexibilidade dos ligantes e receptores. Química Nova. 2005;28: 95-102.
Vincenzi M, Mercurio FA., Leone M. Looking for SARS-CoV-2 therapeutics through computational approaches. Curr Med Chem. 2023;30:3158-3214.
World Health Organization. WHO. Coronavirus disease (COVID-19) pandemic: Coronavirus disease (COVID-19) pandemic: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed in march, 2024.
» https://www.who.int/emergencies/diseases/novel-coronavirus-2019
Yoneda JD, Albuquerque MG, Leal KZ, Santos FC, Batalha PN, Brozeguini L, et al. Docking of anti-HIV-1 oxoquinoline-acylhydrazone derivatives as potential HSV-1 DNA polymerase inhibitors. J Mol Struct . 2014;1074:263-270.
Zarros A. Computational drug screening in COVID-19 drug repurposing research: Encouraging findings and limitations. J Expl Res Pharmacol. 2022;7:3-4.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
